Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Research Article
Quantitation of Insulin Analogue Glargine and Its Two Metabolites M1 and M2 on Triple Quad 6500 and Triple TOF 5600 LC-MS/MS Systems in a Dog Toxicokinetics Study
Yong-Xi Li1*, Yan Ke1, Junyu Li1, Yu Li2, Run Li2, Xiaofeng Chen2, Sahana Mollah3 and Xu Wang31Medpace, Bioanalytical Laboratories, Cincinnati, Ohio, USA
2HEC Pharma Co. Ltd, 5th Industrial Area Shangsha, China
3AB SCIEX, Framingham, Massachusetts, USA
- *Corresponding Author:
- Yong-Xi Li
Medpace, Bioanalytical Laboratories, 5365 Medpace Way
Cincinnati, Ohio, 45227, USA
Tel: +1-513-579-9911 ext 2070
Fax: +1-513-579-0444
E-mail: y.li@medpace.com
Received date: November 15, 2013; Accepted date: December 18, 2013; Published date: December 20, 2013
Citation: Li YX, Ke Y, Li J, Li Y, Li R, et al. (2013) Quantitation of Insulin Analogue Glargine and Its Two Metabolites M1 and M2 on Triple Quad 6500 and Triple TOF 5600 LC-MS/MS Systems in a Dog Toxicokinetics Study. J Anal Bioanal Tech S5: 004. doi: 10.4172/2155-9872.S5-004
Copyright: © 2013 Li YX, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Glargine is a long lasting bioengineered insulin analogue commonly used in the medical treatment of insulindependent diabetes mellitus. After subcutaneous injection, glargine undergoes enzymatic process generating two metabolites, M1 and M2. Quantitative evidences of their presence and concentration after doping multiple concentrations are important for clinical study. Such information can also help to understand the pharmacokinetics, pharmacodynamics, and toxicology during the insulin drug development. We developed and validated a high throughput analytical method coupled with solid-phase extraction (SPE) and LC-MS/MS for the quantitation of intact insulin in plasma samples for use in pre-clinical and clinical studies. The multiple-reaction-monitoring (MRM) experiments performed on a triple-quadruple mass spectrometry instrument were used for quantitation. A 3.5 min UHPLC method was developed to achieve high throughput. An eight-point standard calibration curve with concentration from 0.2 ng/mL to 20 ng/mL was constructed corresponding to the normal non-fasting insulin levels in plasma. The acceptance criteria for values of accuracy, precision, and linearity of the quantitation curve were developed in accordance to the bioanalytical method validation guidance published by Food and Drug Administration (FDA) and European Medicines Agency (EMA). This validated MRM method was applied for toxicity study of insulin analogues in dog. The toxicokinetic results were reported. Moreover, we compared the MRM results to the MS quantitation results acquired on a hybrid quadruple-quadruple time-of-flight (QqTOF) and showed the high resolution instrument can be an option for peptide and biotherapeutic protein quantitation.
